BONEX Share Price Performance
SEK 204.00
-146.80 (-41.85%)
45.0% undervalued intrinsic discount
SEK 370.60
Fair Value
Price SEK 204.00
AnalystConsensusTarget SEK 370.60
AnalystHighTarget SEK 428.00
Fair ValueSEK 370.60
Share Pricen/a
Bonesupport Holding AB (publ) Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 40 Fair Values set on narratives written by author
BONEX Community Narratives
AN
Fair Value SEK 370.6 45.0% undervalued intrinsic discount
Positive Clinical Results And US Launch Will Drive Future Success
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
Fair Value SEK 428 52.3% undervalued intrinsic discount
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 428
52.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
35.55% p.a.
Profit Margin
28.48%
Future PE
41.48x
Price in 2029
SEK 499.81
Positive Clinical Results And US Launch Will Drive Future Success
Key Takeaways High repeat usage and indication expansion in the U.S. drive strong growth for CERAMENT G, enhancing future revenue prospects and market share. Upcoming FDA approvals and reimbursement adjustments, alongside strategic marketing investments, are expected to boost revenue and margins across underpenetrated markets.Read more
224
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
SEK 370.6
45.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
31.48% p.a.
Profit Margin
29.14%
Future PE
37.94x
Price in 2029
SEK 426.98
Trending Discussion
Recently Updated Narratives
AN
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Fair Value: SEK 428 52.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BONEX: De Novo Shift Will Support Long Term Upside Potential
Fair Value: SEK 370.6 45.0% undervalued intrinsic discount
24 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bonesupport Holding AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 22, 2026
- 2.13
- 92.57%
- 12.10%
- 0%
About BONEX
- Founded
- 1999
- Employees
- 143
- CEO
- WebsiteView website
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.
